UNLABELLED: Twenty-five patients with refractory, metastatic carcinoma of the breast were treated with continuous ambulatory 5-fluorouracil (5 FU) infusion (200 to 300 mg/m2/day) through a chronic indwelling central venous catheter. All patients had had extensive previous treatment, including hormonal therapy in 20/25 patients (80%), radiation therapy in 18/25 patients (72%), and an average of 4.6 previous chemotherapy drugs per patient (range 1-10). Twenty-three of 25 patients (92%) had had previous bolus 5 FU. Seventeen of 25 patients (68%) had two or more metastatic sites of involvement and 17/25 patients (68%) had visceral involvement. RESULTS: complete remission-1/25 (4%), partial remission-7/25 (28%), stable disease-6/25 (24%), and progressive disease-11/25 (44%), for an overall response rate of 8/25 (32%). Median duration of response was 6 months. Toxicities included hand-foot syndrome, mucositis, diarrhea, and nausea and vomiting, and required treatment interruption and/or dose attenuation in 9/25 patients (36%). No myelosuppression or serious catheter-related problems were seen. We conclude that continuous 5 FU infusion is a potentially effective salvage treatment that may provide meaningful palliation in some patients with carcinoma of the breast, in spite of extensive previous treatment.
UNLABELLED: Twenty-five patients with refractory, metastatic carcinoma of the breast were treated with continuous ambulatory 5-fluorouracil (5 FU) infusion (200 to 300 mg/m2/day) through a chronic indwelling central venous catheter. All patients had had extensive previous treatment, including hormonal therapy in 20/25 patients (80%), radiation therapy in 18/25 patients (72%), and an average of 4.6 previous chemotherapy drugs per patient (range 1-10). Twenty-three of 25 patients (92%) had had previous bolus 5 FU. Seventeen of 25 patients (68%) had two or more metastatic sites of involvement and 17/25 patients (68%) had visceral involvement. RESULTS: complete remission-1/25 (4%), partial remission-7/25 (28%), stable disease-6/25 (24%), and progressive disease-11/25 (44%), for an overall response rate of 8/25 (32%). Median duration of response was 6 months. Toxicities included hand-foot syndrome, mucositis, diarrhea, and nausea and vomiting, and required treatment interruption and/or dose attenuation in 9/25 patients (36%). No myelosuppression or serious catheter-related problems were seen. We conclude that continuous 5 FU infusion is a potentially effective salvage treatment that may provide meaningful palliation in some patients with carcinoma of the breast, in spite of extensive previous treatment.
Authors: E Quebbeman; R Ausman; R Hansen; T Becker; G Caballero; P Ritch; D Jenkins; D Blake; L Tangen; W Schulte Journal: J Surg Oncol Date: 1985-09 Impact factor: 3.454
Authors: L Repetto; L Miglietta; G Gardin; C Lanfranco; C Naso; L Merlini; S Giudici; A Venturino; E Campora; F Testore Journal: Breast Cancer Res Treat Date: 1994 Impact factor: 4.872
Authors: Kathryn M Camacho; Stefano Menegatti; Douglas R Vogus; Anusha Pusuluri; Zoë Fuchs; Maria Jarvis; Michael Zakrewsky; Michael A Evans; Renwei Chen; Samir Mitragotri Journal: J Control Release Date: 2016-03-24 Impact factor: 9.776
Authors: K J O'Byrne; M I Koukourakis; M P Saunders; A J Salisbury; R Isaacs; S Varcoe; M Taylor; T S Ganesan; A L Harris; D C Talbot Journal: Br J Cancer Date: 1998-06 Impact factor: 7.640
Authors: J Y Pierga; M Jouve; B Asselain; A Livartowski; P Beuzeboc; V Diéras; S Scholl; T Dorval; T Palangié; E Garcia-Giralt; P Pouillart Journal: Br J Cancer Date: 1998-05 Impact factor: 7.640
Authors: B Chevallier; P Bastit; Y Graic; J F Menard; J P Dauce; J P Julien; B Clavier; A Kunlin; J D'Anjou Journal: Br J Cancer Date: 1993-03 Impact factor: 7.640